Loading data for TECH — first visit, this takes a few seconds.

Alerta

Bio-Techne Corporation (TECH)

NasdaqGS: TECH · Precio en tiempo real · USD

72.50

+0.28 (0.39%)

Al cierre: Aug 18, 2026, 3:59 PM

0.39% (1D)

Precio de compra	n/a
Capitalización de mercado	11.3B
Ingresos (TTM)	1.22B
Beneficio neto (TTM)	181.86M
Beta	1.28
EPS (TTM)	1.16
Ratio PER (TTM)	62.5
Adelante PE	31.29
P/B (TTM)	5.44
P/S (TTM)	9.30
Earnings Date	Nov 9, 2026

Precio de venta	n/a
Volumen	1,038,703
Volumen medio (20D)	4,828,153
Abierto	72.39
Anterior Cerrar	72.22
Rango del día	72.38 - 72.56
Rango de 52 semanas	43.20 - 72.62
analista	n/a
Precio objetivo	n/a
Dividendos	$0.32 (0.44%)
Fecha ex dividendo	24 ago 2026

Acerca de TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cel...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Feb 9, 1989

Empleados 3,000

Bolsa de Valores NasdaqGS

Símbolo bursátil TECH

Sitio web https://www.bio-techne.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Bio-Techne fueron 1.22B, un aumento de 5.23% en comparación con 1.16B del año anterior. Las ganancias fueron 73.4M, una disminución de -56.34%.

Estados financieros

Sorpresa de resultados

Bio-Techne ha publicado sus resultados trimestrales en Aug 12, 2026:

Ingresos de $311.42M falla las estimaciones por $0, con -1.51% Disminución interanual.

EPS de 0.52 falla las estimaciones por 0.00, con -1.89% Disminución interanual.

Próxima publicación de resultados

Está previsto que Bio-Techne Corporation publique sus resultados el Nov 9, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 día hace · Barchart

Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

1 día hace · StockStory

3 High-Flying Stocks We Approach with Caution

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

6 días hace · Zacks

TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

1 semana hace · StockStory

Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 pe...

1 semana hace · Simply Wall St.

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?

Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at ...

Página 1 de 2

Bio-Techne Corporation (TECH)